HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 09, September 2021 – The Rise of Alternative Proteins       » The Key to Improving Iron Content in Crops       » Breeding Non-GMO Plants With Next-Generation Chloroplast Gene-Editing       » New Lipomer Can Now Safely Deliver RNA Drugs to Lungs       » Preventing Deadly Post-Transplant Infection With Llama Nanobodies       » Insulin-Producing Implants: The Future of Care for Type 1 Diabetes      
Vol 25, No. 09, September 2021   |   Issue PDF view/purchase
EYE ON CHINA
Pre-Engraftment Syndrome: Why it Happens and How to Treat it
An 8 year-long study has revealed the pathogenesis of pre-engraftment syndrome and a therapeutic strategy to control clinical symptoms and reduce mortality.

Researchers from the University of Science and Technology of China have collaborated with the First Affiliated Hospital of the university to reveal the pathological mechanism of severe pre-engraftment syndrome after umbilical cord blood transplantation. Their novel work, published in Nature Communications, has provided a treatment strategy for patients with the condition and is expected to significantly improve the curative effect of unrelated cord blood transplantation.

Unrelated cord blood transplantation refers to a type of treatment that is often used to cure haematological malignancies, hematopoietic disorders, congenital immunodeficiency, and some genetic metabolic diseases. Since its first successful clinical application to treat malignant haematological diseases in children in 2000, this technique has earned itself a good reputation as an effective and attractive therapeutic approach. To date, the First Affiliated Hospital of the University of Science and Technology of China has completed 1519 cases of unrelated cord blood transplantation, earning international recognition as an umbilical cord blood transplantation centre.

The reason for its success is largely because the incidences of chronic graft-versus-host disease, which is a condition that might occur after an allogeneic transplant, is low and mild. As such, patients can still achieve a high quality of life even after the transplantation.

But where there are strengths, there are weaknesses. Like all medications and therapeutics, unrelated cord blood transplantation comes with its own fair share of limitations and challenges. One of the greatest obstacles of performing unrelated cord blood transplantation is tackling the post-surgery side effects.

In the early stages after unrelated cord blood transplantation, 70 to 80 per cent of recipients have been reported to suffer from pre-engraftment syndrome. Pre-engraftment syndrome is characterised by high fever, rash, and diarrhoea, among other symptoms, that occur during or prior to neutrophil recovery. Severe cases of pre-engraftments syndrome are associated with high mortality and morbidity. Unfortunately, the exact mechanisms behind this syndrome have remained elusive to clinicians and scientists alike, until now.

After nearly eight years of research, Professors Wei Haiming, Tian Zhigang, Sun Zimin, and colleagues have finally uncovered the pathogenesis of the pre-engraftment syndrome. They have also reported successful results of a clinical trial that tested a potent drug to control the pathology of the syndrome.

Early on in the investigation, the team first analysed the peripheral blood of patients who underwent unrelated cord blood transplantation. It was then that they noticed that patients with the pre-engraftment syndrome displayed higher amounts of inflammatory monocytes. Upon closer inspection, it was revealed that these monocytes came from cord blood and were the main source of proinflammatory cytokines like GM-CSF and IL-6, which drive the pathology of pre-engraftment syndrome.

Their conclusion was that after a patient receives unrelated cord blood transplantation, inflammatory monocytes derived from the cord blood rapidly expand in the body of the recipient, thereby increasing the levels of cytokines GM-CSF and IL-6 in their blood, which leads to the manifestation of pre-engraftment syndrome.

Having uncovered the pathogenesis of pre-engraftment syndrome, the team proceeded to conduct a clinical trial using tocilizumab, an inhibitor of the IL-6 receptor, among patients with severe cases of the syndrome. The results of the clinical trials were successful and the team reported that tocilizumab was not only capable of significantly controlling the clinical symptoms of pre-engraftment syndrome, but also reducing the mortality of patients. A 100-day follow up after the treatment showed that none of the patients experienced non-relapse mortality.

Given the promising results of tocilizumab’s anti-inflammatory effects, the study is expected to serve as a practical guide for the university to propose and implement treatment plants using tocilizumab for patients with not only pre-engraftment syndrome but also COVID-19 and pneumonia. Currently, the treatment plan has been approved by the U.S. Food and Drug Administration and the National Health Service to be used in clinical applications.


Source: Jin et al. (2021). Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients. Nature Communications, 12, 4317.

NEWS CRUNCH  
news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
news TechInnovation Returns from 28 to 30 September 2021
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy